These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 16647907

  • 1. The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.
    Gol M, Baris N, Guneri S, Posaci C.
    Am J Obstet Gynecol; 2006 May; 194(5):1249-54. PubMed ID: 16647907
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL, Song J, Dowsett SA, Mershon JL, Delmas PD, Secrest RJ, Cauley JA.
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF, Tsai YW, Wen YW, Hsiao FY, Kuo KN, Tsai CR.
    Menopause; 2010 Mar; 17(1):57-63. PubMed ID: 19680161
    [Abstract] [Full Text] [Related]

  • 9. Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.
    Scharla S, Oertel H, Helsberg K, Kessler F, Langer F, Nickelsen T.
    Curr Med Res Opin; 2006 Dec; 22(12):2393-402. PubMed ID: 17257453
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.
    Qu Y, Wong M, Thiebaud D, Stock JL.
    Curr Med Res Opin; 2005 Dec; 21(12):1955-9. PubMed ID: 16368046
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.
    Sebastián-Ochoa A, Fernández-García D, Reyes-García R, Mezquita-Raya P, Rozas-Moreno P, Alonso-Garcia G, Muñoz-Torres M.
    Menopause; 2012 Feb; 19(2):172-7. PubMed ID: 21971209
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.
    Aldrighi JM, Quail DC, Levy-Frebault J, Aguas F, Kosian K, Garrido L, Bosio-Le Goux B, Saráchaga M, Graebe A, Niño AJ, Nickelsen T.
    Am J Obstet Gynecol; 2004 Dec; 191(6):1979-88. PubMed ID: 15592280
    [Abstract] [Full Text] [Related]

  • 20. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, Martino S.
    Clin Cancer Res; 2006 Sep 01; 12(17):5242-7. PubMed ID: 16951244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.